
MinervaX Announces Award of 4.4 Million Euro in Investment from Novo Holdings REPAIR Impact Fund and Sunstone Capital for Further Clinical Development of the Company’s Vaccine Against Group B Streptococcus (GBS) 21 January 2019
MinervaX, a privately held Danish biotech company, announces today that is has been awarded an in... Read more






